News

People with myasthenia gravis suffer from diverse patterns of muscle weakness, which tend to shift frequently throughout the disease’s course, a new study shows. The study, “Heterogeneity and Shifts in Distribution of Muscle Weakness in Myasthenia Gravis,” was published in the journal Neuromuscular Disorders. Myasthenia gravis (MG) is…

Treatment with Soliris (eculizumab) provides comparable and sustained improvements in daily living and muscle strength in Japanese and Caucasian patients with treatment-resistant generalized myasthenia gravis (gMG), according to one-year data of REGAIN’s extension study. Efficacy and safety were maintained up to 52 weeks in both patient groups and were consistent…

Analyzing microbial and metabolic changes in fecal samples may provide a highly reliable way to diagnose myasthenia gravis (MG) and monitor its severity, according to a new study in patients and mice. The research, “Perturbed Microbial Ecology in Myasthenia Gravis: Evidence from the Gut Microbiome and…

The use of blood cholesterol-lowering medications called statins is linked to a small risk of myasthenia gravis (MG), according to a large World Health Organization database study. The study, “Statin‐induced myasthenia: a disproportionality analysis of the WHO’s VigiBase pharmacovigilance database,” was published in the journal Muscle&Nerve. Statins…